What’s Going On With Grom Social Enterprises Stock?

Grom Social Enterprises Inc. (NASDAQ: GROM) shares are trading higher Thursday, despite a lack of company-specific news.

Grom Social Enterprises Inc. (NASDAQ:GROM) shares are trading higher Thursday, despite a lack of company-specific news. Here’s a look at what’s going on:

What To Know:

Shares of GROM are moving Thursday on very heavy trading volume. According to data from Benzinga Pro, more than xx shares have already been traded in the session, compared to the stock’s 100-day average of just over 268 thousand shares.

Grom Social Enterprises, Inc. is a media, technology and entertainment company focused on delivering content to children under the age of 13 years through a secure platform that can be monitored by parents or guardians. 

Grom Social Enterprises’ shares have garnered the attention of short-sellers and retail investors alike. GROM is one of the top trending tickers on Yahoo! Finance, and 11.85% of shares are being sold short, according to data from Benzinga Pro. 

Related News: What’s Going On With ChargePoint Holdings Stock? 

GROM Price Action: According to Benzinga Pro, GROM shares are up 25% at $2.19 at the time of publication.

Image: StockSnap from Pixabay

Total
0
Shares
Related Posts
Read More

Voya Investment Management And The Illinois Bankers Association Enter Into A Preferred Vendor Agreement To Provide Illinois And Other Community Banks A Commercial And Industrial Loan Acquisition And Risk Management Program

Voya Investment Management, the asset management business of Voya Financial, Inc. (NYSE:VOYA), and the Illinois Bankers Association (IBA) announced today that they have entered into a commercial and industrial (C&I)

VOYA

Read More

Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma’s Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trial

During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin recep

RYTM